TK inhibitor

Oncology Venture formed an additional Danish oncology therapeutic spin-out for the development of a specific drug against cancer utilizing DRP, OV-SPV2 APS.

OV-SPV2 intends to test and potentially develop an oral tyrosine kinase inhibitor from Novartis that owns the worldwide rights to the anticancer drug.
The drug candidate has been tested in Phase 2 and Phase 3 studies. Data are available from the studies. Oncology Venture ApS has the possibility to implement a fast DRP test on available data in order to assess if the DRP tool can identify responders from the clinical trials.

TK inhibitor